Concurrent IDH1 and IDH2 mutations in glioblastoma: A case report

Article Clinical Neurology

Molecular marker testing and reporting completeness for adult-type diffuse gliomas in the United States

Corey Neff et al.

Summary: This study investigated the testing and reporting completeness of a newly developed brain molecular marker (BMM) in the US. The overall completeness was 81.1%, with variations among different subgroups and hospital attributes.

NEURO-ONCOLOGY PRACTICE (2023)

Add to Collection

Article Medical Laboratory Technology

Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas

Daniel J. Brat et al.

Summary: This article provides evidence-based recommendations for molecular biomarker testing in diffuse gliomas (DGs) and suggests appropriate laboratory methods and biomarkers selection to inform clinical management.

ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Implications of Concurrent IDH1 and IDH2 Mutations on Survival in Glioma-A Case Report and Systematic Review

Alexander Yuile et al.

Summary: Mutations in both IDH1 and IDH2 play an important role in the development of gliomas, but the co-occurrence of IDH1 and IDH2 mutations in the same tumor is rare. This study describes a case of an IDH-mutant astrocytoma with both IDH1 and IDH2 mutations, and the patient remains disease-free after nine and a half years. Interrogation of cancer genomic databases and a systematic review confirm the rarity of the concurrent mutations.

CURRENT ISSUES IN MOLECULAR BIOLOGY (2022)

Add to Collection

Review Oncology

The implications of IDH mutations for cancer development and therapy

Christopher J. Pirozzi et al.

Summary: The article discusses the impact of IDH mutations in various cancers, highlighting the production of oncometabolite and the importance of targeting mutant IDH for therapeutic purposes. It reviews the current understanding and available data on therapeutic strategies for IDH-mutant cancers and speculates on whether treatment approaches will converge or be context dependent based on the underlying pathogenesis.

NATURE REVIEWS CLINICAL ONCOLOGY (2021)

Add to Collection

Review Oncology

The 2021 WHO Classification of Tumors of the Central Nervous System: a summary

David N. Louis et al.

Summary: The fifth edition of the WHO Classification of Tumors of the Central Nervous System integrates molecular diagnostics into CNS tumor classification, introduces different approaches to tumor nomenclature and grading, and emphasizes the importance of integrated diagnoses and layered reports.

NEURO-ONCOLOGY (2021)

Add to Collection

Review Pathology